PBLS
NASDAQ HealthcareParabilis Medicines, Inc. - Common Stock
Biotechnology
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $29.06 |
|---|---|
| 成交量 | 517,434 |
| 市值 | 3.55B |
| RSI（14日） | 59.6 |
| 52周最高 | $34.47 |
| 52周最低 | $24.51 |
| Forward P/E | -15.29 |
| Price / Book | -0.17 |
🎯 投资策略评分
PBLS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (59/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (5/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 PBLS in your text
粘贴任何文章、记录或帖子 — 工具将提取 PBLS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.